Nelson Mullins Riley & Scarborough LLP represented Apimeds Pharmaceuticals US, Inc. (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company, in the closing of its initial public offering on the NYSE American, LLC (the “NYSE American”). The Company’s shares began trading on the NYSE American on May 9, 2025 under the symbol “APUS.”

The Nelson Mullins team was led by partners David Mannheim and Mike Bradshaw, and associates Kathryn Simons and Ashley Wu.

Apimeds sold approximately 3.4 million shares of common stock at the public offering price of $4.00 per share, with the offering raising $13.5 million in gross proceeds, before deducting underwriting discounts and commissions and other related expenses payable by Apimeds.

Apimeds is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. The Company expects to use the net proceeds from the sale of the shares to fund a Phase III clinical trial in knee osteoarthritis, to initiate at least one non-registered corporate sponsorship study in multiple sclerosis, to manufacture its product candidate, and to address general working capital needs.

D. Boral Capital LLC acted as sole book-running manager for the offering.

Click here to learn more. 

Established in 1897, Nelson Mullins is a full-service Am Law 100 firm of more than 1,000 attorneys, policy advisors, and professionals with offices across the United States. For more information, go to www.nelsonmullins.com.